Ambulero

We are pleased to announce that Randy Berholtz, our Board Chair, will present Ambulero at the upcoming Cell & Gene Therapy Summit on March 3, 2025 hosted by Charles River. More information can be found here: https://lnkd.in/eiVPf3Xp &sms=7&cn=9eAXHJAvQ--xG3HNGeFCeQ

We��re delighted to see a request for supplemental funding approved by NHLBI��s Catalzye Program: a division of NIH supporting development of promising therapeutic candidates for clinical testing. Funds will be used to help complete IND-enabling work for Ambulero��s AMB-301 gene therapy to treat a rare vascular disease.??

AAV Gene Therapy Shows Promise for Preventing Limb and Tissue Loss: New Findings from Ambulero��s Chief Scientific and Medical Officers Published in the Annals of Surgery Ambulero is excited to announce groundbreaking findings published in the?Annals of Surgery (link below).?Lead investigators, Omaida C. Velazquez, MD, FACS and Zhao-Jun Liu, MD, PhD, along with co-investigators from the University of Miami and the University of Florida��s Powell Gene Therapy Center, report on a promising vascular regeneration gene therapy (exclusively licensed to Ambulero) that could salvage diseased ischemic limbs and one day eliminate the need for amputation. Gene therapy for vascular regeneration, while holding great promise, faces challenges. One of them is producing enough vector to treat an entire human limb cost-effectively. The current study, funded by the?Catalyze Program of NHLBI (NIH), provides compelling animal data indicating that that the scale-up to an entire human limb is feasible using codon optimization of Ambulero��s??lead E-selectin/AAV vector. Extrapolation based on cornerstone data demonstrates that the estimated therapeutically effective dose is economically feasible for starting human clinical trials. This work??provides a data-driven runway for first-in-human clinical testing of our AAV-gene therapy to treat a rare vascular disease.??The human scale-up considerations derived from this work are also consistent with current manufacturing capabilities of established contract research organizations (CROs). This research demonstrates that Ambulero��s novel gene therapy may offer a viable and cost-effective solution for patients suffering from chronic limb-threatening ischemia (CLTI) and other unsolved vascular diseases that can lead to loss of circulation, tissue decay, and limb amputation. For more information, please contact:? Robert L. Buchanan, CEO [email protected] https://lnkd.in/ewdnbi8v

Some good news at the end of the week for Ambulero and other companies advancing treatments for rare diseases. This week, the U.S. FDA announced the creation of a rare disease?innovation hub?to help advance new treatments and build connections between developers and the rare disease community. We are looking forward to participating in this new program. https://lnkd.in/egJKYwvs?

ABC World News Tonight?with David Muir is one of the most popular televised news programs in the United States. Last night, the US Centers For Disease Control (CDC) ran a segment on the program about an amputee with Buerger��s Disease (BD): a rare vascular disease and Ambulero��s first indication. Ambulero is developing a first-in-class gene and cell therapy platform that may eliminate amputation as a care option for patients with BD and other severe vascular diseases should future clinical testing be successful. The link below provides a longer version of the CDC segment that aired on the program: https://lnkd.in/eHi-vFV6

Ambulero is a proud member of the 2023-2024 cohort of young companies in the NYU/Stern School of Business Endless Frontier Labs (EFL) small business incubator. The EFL produced a report (link below) which benchmarks the incubator against Y Combinator, Mass Challenge and others. It shows that based on metrics like capital raised and creation of star companies, the EFL is the No. 1 program for science and technology-based startups. Congratulations NYU/Stern EFL for this well-earned distinction! https://lnkd.in/e2jza2gJ

There is increasing interest in the development of new muscle-building agents that prevent lean muscle loss associated with trauma, cachexia, old age and other causes. Novel agents that can reverse muscle wasting effects of popular anti-obesity drugs such as GLP-1 agonists are also of significant interest. Drs Omaida C. Velazquez and Zhao-Jun Liu of the University of Miami Miller School of Medicine found that E-selectin/AAV gene therapy promotes robust myogenesis and skeletal muscle recovery in animal models of limb ischemia and vascular disease. Ambulero has exclusively licensed IP protecting this discovery and is supporting efforts to bring this innovation to the clinic. Should future clinical testing be successful, we believe the therapeutic building of muscle mass will become an integral part of all limb salvage protocols for patients.?

On May 8-9, 2024 Ambulero will be in New York City to graduate from the NYU Stern School of Business small company incubator called the Endless Frontiers Lab.?We��re tremendously fortunate to have been selected to be part of the 2023-2024 class. Participation has sharpened our corporate message and introduced us to new investors, mentors and colleagues.?To learn more about this valuable small business program, click the link below.? https://lnkd.in/erbW7tZg

We were happy to present the company at the 2024 South Florida Life Sciences Showcase held in Miami, Florida. Lots of interest around our cell and gene therapy programs for addressing vascular disease and non-healing wounds. Thank you BioFlorida for the invitation! https://lnkd.in/eEy2xKge?